Cerity Partners LLC Buys 9,495 Shares of Elevance Health, Inc. $ELV

Cerity Partners LLC lifted its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 11.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 95,932 shares of the company’s stock after buying an additional 9,495 shares during the period. Cerity Partners LLC’s holdings in Elevance Health were worth $33,631,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ELV. Rossby Financial LCC boosted its position in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares in the last quarter. ORG Partners LLC boosted its position in Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares in the last quarter. Dorato Capital Management bought a new stake in Elevance Health during the 4th quarter valued at approximately $41,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Elevance Health during the 4th quarter valued at approximately $38,000. Finally, Flagship Harbor Advisors LLC bought a new stake in Elevance Health during the 4th quarter valued at approximately $44,000. 89.24% of the stock is owned by institutional investors.

Elevance Health Trading Down 4.7%

Shares of NYSE ELV opened at $404.33 on Thursday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98. The stock has a market cap of $87.81 billion, a P/E ratio of 17.20, a price-to-earnings-growth ratio of 2.40 and a beta of 0.67. The firm has a 50-day moving average of $362.40 and a 200 day moving average of $343.89. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same period last year, the company posted $11.97 EPS. Elevance Health’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, sell-side analysts expect that Elevance Health, Inc. will post 26.94 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s payout ratio is currently 29.26%.

Analysts Set New Price Targets

Several research firms have weighed in on ELV. Truist Financial lifted their price objective on Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and raised their price objective for the company from $363.00 to $498.00 in a research report on Wednesday, May 20th. Mizuho raised their price objective on Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research report on Monday. Robert W. Baird raised their price objective on Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Finally, UBS Group lifted their price target on shares of Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $416.11.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.